Axsome Therapeutics, Inc. (AXSM) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

SA Transcripts 162.14K Followers Follow Axsome Therapeutics, Inc. ( AXSM ) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 3:45 PM EDT Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie - Chief Financial Officer Conference Call Participants Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Presentation Benjamin Burnett Wells Fargo Securities, LLC, Research Division Okay. We'll go ahead and get started with the next one. I'm Ben Burnett, biotech analyst at Wells Fargo. Pleased to be here with the Axsome management team. We have Nick Pizzie, CFO. And then to his right, we have Mark Jacobson, COO. Thank you all. Mark Jacobson Chief Operating Officer Thanks for having us. Nick Pizzie Chief Financial Officer Great to be here. Benjamin Burnett Wells Fargo Securities, LLC, Research Division I think just to kick it off, maybe we could just start by -- if you just give us kind of a quick overview of Axsome and just kind of frame any near-term catalysts that we should focus on. Mark Jacobson Chief Operating Officer Sure. I'd be happy to. And maybe I'll start and then hand it over to Nick. But Axsome, CNS-focused biopharma, we have 3 products that are commercial products. Those are AUVELITY for major depressive disorder and agitation associated with Alzheimer's disease. There's SYMBRAVO for migraine, and SUNOSI for excessive daytime sleepiness and obstructive sleep apnea and narcolepsy. All products are growing robustly. Nick can share some of those numbers. And of course, for AUVELITY, we have recently expanded that team. So we are seeing robust growth beginning in major depressive disorder, or I should say, continuing. And then the launch effort around the newest indication, Alzheimer's disease agitation, is underway. And so both of those efforts are -- have started to come online this summer. We can get into the details, but that's the commercial business.